Showing 1501-1510 of 1716 results for "".
From Training to Transformation: How Leaders Get the Most Out of Educating Their Team
https://practicaldermatology.com/issues/september-2025/from-training-to-transformation-how-leaders-get-the-most-out-of-educating-their-team/37640/Imagine investing thousands of dollars in staff time and tuition for the latest aesthetic techniques or business courses—sending employees to conferences or bringing in an expert for in-office training—only to watch those skills fade, or be underused or forgotten.Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Dr. DiAnne Davis on Mentorship, Lasers, Skin of Color, and More
https://practicaldermatology.com/issues/september-2025/dr-dianne-davis-on-mentorship-lasers-skin-of-color-and-more/37643/In a recent YoungMD Connect virtual mentorship session, DiAnne Davis, MD, FAAD, a dermatologist based in Dallas, discussed her journey from patient to dermatologist, the influence of mentorship, and her commitment to advancing safe, effective cosmetic procedures for patients with skin of color.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuComorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.We Are All From Somewhere
https://practicaldermatology.com/issues/july-2025/we-are-all-from-somewhere/36504/Everyone in dermatology has a story about where it all started and where choices were made to lead to the next steps. The common themes are baby steps, gratitude, and not closing the door behind them.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/the-latest-on-systemic-agents-for-psoriasis/29073/The pharmacologic pipeline continues to produce strong options for systemic treatment of psoriasis. Practical Dermatology® spoke with Editorial Board member Jashin J. Wu, MD, FAAD, Founder and CEO of the Dermatology Research and Education Foundation, to discuss the latest treatment considerations wi